financetom
Business
financetom
/
Business
/
Colgate-Palmolive reaches $332-million settlement with employees over pensions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Colgate-Palmolive reaches $332-million settlement with employees over pensions
Sep 2, 2025 7:50 AM

NEW YORK, Sept 2 (Reuters) - Colgate-Palmolive ( CL )

agreed to pay $332 million to settle a long-running class-action

lawsuit accusing the consumer products company of making

mistakes in calculating its employees' pensions.

A preliminary settlement covering 1,177 employees was filed

on Friday night in Manhattan federal court and requires a

judge's approval. Employees would receive about $232.7 million

after lawyers' fees and expenses are deducted.

The case had its origins in 1989, when Colgate converted its

pension plan to a cash balance plan and let participants receive

benefits in lump sums.

Colgate amended its plan in 2005 to retroactively award

annuity payments to participants who received lump sums but had

not received the full value of their benefits. The plaintiffs

said Colgate erred in calculating those payments.

Litigation over Colgate's pensions began in 2007, and

Friday's settlement addresses a lawsuit filed in 2016.

Colgate denied wrongdoing and said it settled to avoid the

risk and expense of more litigation. It did not immediately

respond to a request for comment.

The New York-based company set aside money for the

settlement in the first quarters of 2023 and 2025.

Other Colgate brands include Hill's Pet Nutrition, Irish

Spring, Speed Stick, Lady Speed Stick, and Tom's of Maine.

The case is McCutcheon et al v. Colgate-Palmolive Co ( CL ) et al,

U.S. District Court, Southern District of New York, No.

16-04170.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate
Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate
Nov 11, 2024
07:47 AM EST, 11/11/2024 (MT Newswires) -- Unicycive Therapeutics ( UNCY ) said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025. The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company...
First Watch Restaurant to Acquire 16 Franchise Restaurants in Carolinas
First Watch Restaurant to Acquire 16 Franchise Restaurants in Carolinas
Nov 11, 2024
07:46 AM EST, 11/11/2024 (MT Newswires) -- First Watch Restaurant Group ( FWRG ) said Monday it has agreed to buy 15 of its franchise-owned restaurants, one under-construction restaurant, and corresponding development rights for $49 million in Carolinas. The company intends to finance the acquisition, expected to be completed by mid-April next year, through cash and available borrowings under its...
Top Premarket Decliners
Top Premarket Decliners
Nov 11, 2024
07:49 AM EST, 11/11/2024 (MT Newswires) -- Dogwood Therapeutics ( DWTX ) shares slumped nearly 30% pre-bell Monday following a 2.3% loss in the previous session. Sapiens (SPNS) shares retreated 21% after the company reported Q3 revenue that trailed analysts' estimates. Monday.com ( MNDY ) shares fell 14% following a 1.8% gain in the previous session. Vision Marine Technologies (...
NuCana Reports 'Encouraging' Data From Study to Treat Patients With Lung Cancer
NuCana Reports 'Encouraging' Data From Study to Treat Patients With Lung Cancer
Nov 11, 2024
07:48 AM EST, 11/11/2024 (MT Newswires) -- NuCana ( NCNA ) said Monday that initial data from an ongoing Phase 1b/2 study of NUC-3373 in combination with pembrolizumab indicated a significant reduction in tumor volume in patients with lung cancer. NUC-3373 may be an attractive alternative to pemetrexed in patients with NSCLC and mesothelioma, David Harrison, NuCana's ( NCNA )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved